Additionally, this strategy is supported by cases like MYH2 myopathies, which are characterized by increased basal myosin ATP consumption and a reduced SRX state in vivo (14), reinforcing the promise of myosin inhibition as a therapeutic strategy for a broad spectrum of skeletal myopathies. This evidence concerns the gene MYH14 and Skeletal myopathy.